To assess the impact of genotypic susceptibility score (GSS) on combined antiretroviral therapy (cART) outcomes during primary HIV infection (PHI) we retrospectively enrolled patients with PHI diagnosed between 2008 and 2015 at 9/24 Italian Network ACuTe HIV InfectiON centers. One hundred-seventy-six patients were enrolled. Of these, 55 (32.9%) patients started with more than three drugs and 11 (7.2%) started with a GSS < 3. Regimen's GSS (per 1 point increase) (adjusted odds ratio [aOR], 4.82; 95% confidence interval [CI], 1.62-14.28; P =.005) and baseline HIV-RNA (per 1 log10 increase) (aOR, 2.02; 95% CI, 1.09-3.73; P =.025) resulted associated with early cART initiation. In conclusion, regimen's GSS resulted to be associated to the time to cART initiation during PHI.
Impact of genotypic susceptibility score on cART outcomes during primary HIV infection / Giacomelli, A.; Fabbiani, M.; De Benedetto, I.; Nozza, S.; Foca, E.; Celesia, B. M.; Marchetti, G.; Mussini, C.; Antinori, A.; D'Ettorre, G.; Madeddu, G.; Bandera, A.; Muscatello, A.; Rusconi, S.. - In: JOURNAL OF MEDICAL VIROLOGY. - ISSN 0146-6615. - 91:10(2019), pp. 1891-1895. [10.1002/jmv.25517]
Impact of genotypic susceptibility score on cART outcomes during primary HIV infection
d'Ettorre G.;
2019
Abstract
To assess the impact of genotypic susceptibility score (GSS) on combined antiretroviral therapy (cART) outcomes during primary HIV infection (PHI) we retrospectively enrolled patients with PHI diagnosed between 2008 and 2015 at 9/24 Italian Network ACuTe HIV InfectiON centers. One hundred-seventy-six patients were enrolled. Of these, 55 (32.9%) patients started with more than three drugs and 11 (7.2%) started with a GSS < 3. Regimen's GSS (per 1 point increase) (adjusted odds ratio [aOR], 4.82; 95% confidence interval [CI], 1.62-14.28; P =.005) and baseline HIV-RNA (per 1 log10 increase) (aOR, 2.02; 95% CI, 1.09-3.73; P =.025) resulted associated with early cART initiation. In conclusion, regimen's GSS resulted to be associated to the time to cART initiation during PHI.| File | Dimensione | Formato | |
|---|---|---|---|
|
Giacomelli_Impact_2019.pdf
accesso aperto
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
84.77 kB
Formato
Adobe PDF
|
84.77 kB | Adobe PDF | |
|
Giacomelli_Impact-genotypic_2019.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
541.02 kB
Formato
Adobe PDF
|
541.02 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
